Article
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
Blood cancer journal - 13 Mar 2015
McGraw K L, Zhang L M, Rollison D E, Basiorka A A, Fulp W, Rawal B, Jerez A, Billingsley D L, Lin H-Y, Kurtin S E, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz M J, Cervera J, Such E, González T, Nevill T J, Haferlach T, Smith A E, Kulasekararaj A, Mufti G, Karsan A, Maciejewski J P, Sokol L, Epling-Burnette P K, Wei S, List A F
Abstract excerpt
Nonsynonymous TP53 exon 4 single-nucleotide polymorphism (SNP), R72P, is linked to cancer and mutagen susceptibility. R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting. Myelodysplastic syndrome (MDS) with chromosome 5q deletion is characterized by erythroid hypoplasia arising from lineage-specific p53 accumulation resulting from ribosomal insufficiency. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.